UROLOGIC CANCER
Clinical trials for UROLOGIC CANCER explained in plain language.
Never miss a new study
Get alerted when new UROLOGIC CANCER trials appear
Sign up with your email to follow new studies for UROLOGIC CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Bladder cancer virus therapy aims to stop tumors from returning
Disease control OngoingThis study tests whether a virus-based treatment called cretostimogene grenadenorepvec can prevent intermediate-risk bladder cancer from returning after surgery. About 367 participants will either receive the treatment or be monitored. The goal is to see if the therapy extends th…
Matched conditions: UROLOGIC CANCER
Phase: PHASE3 • Sponsor: CG Oncology, Inc. • Aim: Disease control
Last updated May 17, 2026 01:01 UTC
-
Bladder cancer drug trial pulled before starting
Disease control TerminatedThis was a planned Phase 3 study testing a drug called NDV-01 (a slow-release combination of two chemotherapy drugs) for people with a type of bladder cancer that did not respond to standard BCG treatment. The goal was to see if the drug could make the cancer disappear, but the s…
Matched conditions: UROLOGIC CANCER
Phase: PHASE3 • Sponsor: Relmada Therapeutics, Inc. • Aim: Disease control
Last updated May 17, 2026 00:48 UTC
-
Bladder cancer drug trial halted before it began
Disease control TerminatedThis study was designed to test if a new drug called NDV-01 could keep bladder cancer from returning after surgery. It was for people with intermediate-risk non-muscle invasive bladder cancer. However, the trial was withdrawn before enrolling any participants, so no results are a…
Matched conditions: UROLOGIC CANCER
Phase: PHASE3 • Sponsor: Relmada Therapeutics, Inc. • Aim: Disease control
Last updated May 14, 2026 12:02 UTC